Genovis launches US operation, recruits American manager

Genovis launches US operation, recruits American manager

Genovis, a biotech company in Lund, Sweden, which develops and markets
innovative products for medical research, has established a subsidiary in
Boston. The new subsidiary will be headed by 
R. Christopher Wilkins.

Due to demand for its products in the US market, Genovis hired Christopher
Wilkins to head its US subsidiary; his responsibilities also include global
marketing initiatives.  

”I'm delighted that Chris chose Genovis," says Sarah Fredriksson, CEO of Genovis
AB. "Staffing is crucial when an operation like Genovis expands internationally.
I'm convinced that Chris will drive the business in the right direction and
enable successful global marketing activities."

Wilkins brings extensive biotech industry experience to the Genovis operation.
He has held executive positions in sales, marketing, and business development at
Cepheid, Inc. and MJ Research, Inc. (owned by Bio-Rad since 2004). He earned his
Ph.D. in Genetics & Biochemistry at Cornell University in Ithaca, New York. 
Genovis has also recently launched a new web site that enables online sales. The
site's first customers were in the US, which is the largest single market for
Genovis products. Consequently, the company decided to establish Genovis Inc.
Going forward, Wilkins will have primary responsibility for global marketing
efforts. 

“Heading up Genovis Inc. and having responsibility for global marketing is a
great challenge," says Wilkins. "The Genovis proposition includes top-quality
products based on innovative technologies that can be utilized in a wide range
of research applications. Building the US organization and enabling the company
to realize its global potential is very exciting.” 

Genovis is currently focusing on two business areas: bimolecular delivery and
antibody engineering. Its product portfolio contains NIMT® FeOsilence, NIMT®
FeOfection, NIMT® FeOlabeling, and NIMT® FabRICATOR. Further product launches
are planned this autumn. While the company's customers are spread across the
entire US, one business-critical region is the Boston area in Massachusetts
where Genovis Inc. is located.


Find out more, contact:
Sarah Fredriksson, CEO, Genovis AB
Tel: +46 46 10 12 35
sarah.fredriksson@genovis.com

Genovis is a biotechnology company with distinguished core competency in the
fields of nanotechnology and nanoparticles. The company's patented NIMT®
technology (NanoInducedMagneticTransfer) has been developed in order to enable
the life science industry to conduct effective preclinical research. Genovis
shares are listed on the First North, part of OMX Nordic Exchange. Mangold
Fondkommission AB is a Certified Advisor and guarantor of liquidity to the
company.